Prima Almazini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Prima Almazini has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Rina Ariani
Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia/National Cardiovascular Centre Harapan Kita, Jakarta, Indonesia
2 shared publications Ahmad Fuady
Department of Community Medicine, Faculty of Medicine Universitas Indonesia, Jakarta
1 shared publicationAmiliana M. Soesanto
Univ Indonesia Hosp, Dept Cardiol & Vasc Med, Jakarta, Indonesia
1 shared publication- Amiliana Mardiani Soesanto
Division of Non‐Invasive Diagnostic and Cardiovascular Imaging, Department of Cardiology and Vascular Medicine, Faculty of Medicine Universitas Indonesia, National Cardiovascular Center Harapan Kita Jakarta Indonesia
1 shared publication - Anwar Santoso
Department of Cardiology and Vascular Medicine, Faculty of Medicine, National Cardiovascular Centre Harapan Kita Hospital Jakarta, Universitas Indonesia, Depok, Indonesia
1 shared publication - Armalya Pritazahra
Department of Cardiology and Medicine, Universitas Indonesia/National Cardiovascular Centre Harapan Kita, Jakarta, Indonesia
1 shared publication
Latest Publications
- Open Access
- 18 March 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (6) , 2051
The Role of Neutrophil-to-Lymphocyte Ratio and Right Ventricular Dysfunction in Indonesian Patients with COVID-19: A Retrospective Cohort Study
Background/Objectives: The clinical impact of neutrophil-to-lymphocyte ratio (NLR) and right ventricular (RV) dysfunction on clinical outcomes in COVID-19 remains understudied in the Indonesian population. This study aims to investigate their prognostic value in hospitalized Indonesian adults with COVID-19. Methods: A retrospective cohort study was conducted at a COVID-19 referral hospital in Indonesia. We included all consecutive adults hospitalized between April 2020 and April 2021 who underwent transthoracic echocardiography (TTE) during admission. Clinical information was extracted from electronic medical records. TTE variables were defined according to the American Society of Echocardiography criteria. Statistical analyses were performed using SPSS. Ethical approval was obtained from the Institutional Review Board of Universitas Indonesia (#2022-01-135). Results: A total of 488 patients were included in this study—29 with and 459 without RV dysfunction. The mean age of the population was 54.8, with 42% being female. An NLR >4.793 was considered elevated. Elevated NLR was independently associated with RV dysfunction (OR: 3.38, p = 0.02). Older age (HR: 1.02, p = 0.01), obesity (HR: 1.85, p < 0.01), chronic kidney disease (HR: 1.69, p = 0.01), high NLR (HR: 2.75, p < 0.001), and RV dysfunction (HR: 2.07, p = 0.02) independently increased the risk of 30-day mortality by multivariate Cox regression analysis. Conclusions: In adult Indonesian patients hospitalized with COVID-19, an elevated NLR was associated with RV dysfunction, and both of these parameters increased the risk of 30-day mortality. This retrospective cohort study highlights the prognostic importance of NLR and RV dysfunction in hospitalized COVID-19 patients, providing physicians with tools to identify high-risk patients.
- 18 March 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (6) , 2051
Open AccessThe Role of Neutrophil-to-Lymphocyte Ratio and Right Ventricular Dysfunction in Indonesian Patients with COVID-19: A Retrospective Cohort Study
Background/Objectives: The clinical impact of neutrophil-to-lymphocyte ratio (NLR) and right ventricular (RV) dysfunction on clinical outcomes in COVID-19 remains understudied in the Indonesian population. This study aims to investigate their prognostic value in hospitalized Indonesian adults with COVID-19. Methods: A retrospective cohort study was conducted at a COVID-19 referral hospital in Indonesia. We included all consecutive adults hospitalized between April 2020 and April 2021 who underwent transthoracic echocardiography (TTE) during admission. Clinical information was extracted from electronic medical records. TTE variables were defined according to the American Society of Echocardiography criteria. Statistical analyses were performed using SPSS. Ethical approval was obtained from the Institutional Review Board of Universitas Indonesia (#2022-01-135). Results: A total of 488 patients were included in this study—29 with and 459 without RV dysfunction. The mean age of the population was 54.8, with 42% being female. An NLR >4.793 was considered elevated. Elevated NLR was independently associated with RV dysfunction (OR: 3.38, p = 0.02). Older age (HR: 1.02, p = 0.01), obesity (HR: 1.85, p < 0.01), chronic kidney disease (HR: 1.69, p = 0.01), high NLR (HR: 2.75, p < 0.001), and RV dysfunction (HR: 2.07, p = 0.02) independently increased the risk of 30-day mortality by multivariate Cox regression analysis. Conclusions: In adult Indonesian patients hospitalized with COVID-19, an elevated NLR was associated with RV dysfunction, and both of these parameters increased the risk of 30-day mortality. This retrospective cohort study highlights the prognostic importance of NLR and RV dysfunction in hospitalized COVID-19 patients, providing physicians with tools to identify high-risk patients.
- 1 October 2024
- Vol. 56 (4) , 571-577
Current Diagnosis and Therapeutic Approach of Functional Mitral Regurgitation.
Functional mitral regurgitation is characterized by normal structures of the mitral valve and chordae tendinea, but the regurgitation occurs due to geometric changes in the left atrium and left ventricle. This condition can contribute to heart failure progression and lead to a poor prognosis. Functional mitral regurgitation is found in approximately one-third of patients with heart failure with a decreased ejection fraction. Echocardiography is the primary work-up for assessing the anatomy and function of the left ventricle, mitral valve, and severity of functional mitral regurgitation. Additionally, for the latter, an integrated qualitative and quantitative assessment is essential to determine the optimal therapeutic strategy. According to the current guidelines, medical therapy remains the main treatment for functional mitral regurgitation. Yet, transcatheter intervention is a safe and effective treatment option in selected patients. While the effect of surgery on improving mortality in patients with functional mitral regurgitation is not established yet, recent guidelines recommend considering surgery for patients who have undergone coronary artery bypass surgery or other cardiac procedures.
- 1 October 2024
- Vol. 56 (4) , 571-577
Current Diagnosis and Therapeutic Approach of Functional Mitral Regurgitation.
Functional mitral regurgitation is characterized by normal structures of the mitral valve and chordae tendinea, but the regurgitation occurs due to geometric changes in the left atrium and left ventricle. This condition can contribute to heart failure progression and lead to a poor prognosis. Functional mitral regurgitation is found in approximately one-third of patients with heart failure with a decreased ejection fraction. Echocardiography is the primary work-up for assessing the anatomy and function of the left ventricle, mitral valve, and severity of functional mitral regurgitation. Additionally, for the latter, an integrated qualitative and quantitative assessment is essential to determine the optimal therapeutic strategy. According to the current guidelines, medical therapy remains the main treatment for functional mitral regurgitation. Yet, transcatheter intervention is a safe and effective treatment option in selected patients. While the effect of surgery on improving mortality in patients with functional mitral regurgitation is not established yet, recent guidelines recommend considering surgery for patients who have undergone coronary artery bypass surgery or other cardiac procedures.
- Open Access
- 11 July 2024
- Published by Radcliffe Medical Media Ltd in Journal of Asian Pacific Society of Cardiology
- Vol. 3
Hypertension and Abnormal Renal Function and the Risk of Ischaemic Stroke in Anticoagulated Type 1 Evaluated Heart Valves, Rheumatic or Artificial Valvular AF
Background: AF substantially increases the risk of stroke. The most widely used risk prediction score for AF is CHA2DS2-VASC. Previous studies have mainly focused on its efficacy among patients with non-valvular AF. The few studies that have considered patients with valvular AF highlight the tool’s poor scoring accuracy. Objective: This study was conducted to evaluate the clinical factors and echocardiographic parameters related to the incidence of ischaemic stroke in anticoagulated evaluated heart valves, rheumatic or artificial (EHRA) type 1 valvular AF patients. Methods: We conducted a retrospective cohort study using data from the Indonesian Registry on Atrial Fibrillation (OneAF). Patients with EHRA type 1 valvular AF recorded in the registry from January 2015 to December 2019 were included in the study. Results: The incidence of ischaemic stroke was 17 (5.2%) out of 329 AF patients with mitral stenosis or mechanical prosthetic valves. A multivariate analysis showed that two clinical factors: hypertension (OR 5.59; 95% CI [1.93–16.15]; p=0.001) and estimated glomerular filtration rate (eGFR) ≤59 ml/min/m2 (OR 3.62; 95% CI [1.30–10.02]; p=0.013), were independently associated with the incidence of ischaemic stroke. No echocardiographic parameters were associated with the incidence of ischaemic stroke in this population. Conclusion: Hypertension and impaired renal function elevated the risk of ischaemic stroke in the patient population. Further research is necessary to determine the proper scoring system for predicting ischaemic stroke in this subgroup.
- 11 July 2024
- Published by Radcliffe Medical Media Ltd in Journal of Asian Pacific Society of Cardiology
- Vol. 3
Open AccessHypertension and Abnormal Renal Function and the Risk of Ischaemic Stroke in Anticoagulated Type 1 Evaluated Heart Valves, Rheumatic or Artificial Valvular AF
Background: AF substantially increases the risk of stroke. The most widely used risk prediction score for AF is CHA2DS2-VASC. Previous studies have mainly focused on its efficacy among patients with non-valvular AF. The few studies that have considered patients with valvular AF highlight the tool’s poor scoring accuracy. Objective: This study was conducted to evaluate the clinical factors and echocardiographic parameters related to the incidence of ischaemic stroke in anticoagulated evaluated heart valves, rheumatic or artificial (EHRA) type 1 valvular AF patients. Methods: We conducted a retrospective cohort study using data from the Indonesian Registry on Atrial Fibrillation (OneAF). Patients with EHRA type 1 valvular AF recorded in the registry from January 2015 to December 2019 were included in the study. Results: The incidence of ischaemic stroke was 17 (5.2%) out of 329 AF patients with mitral stenosis or mechanical prosthetic valves. A multivariate analysis showed that two clinical factors: hypertension (OR 5.59; 95% CI [1.93–16.15]; p=0.001) and estimated glomerular filtration rate (eGFR) ≤59 ml/min/m2 (OR 3.62; 95% CI [1.30–10.02]; p=0.013), were independently associated with the incidence of ischaemic stroke. No echocardiographic parameters were associated with the incidence of ischaemic stroke in this population. Conclusion: Hypertension and impaired renal function elevated the risk of ischaemic stroke in the patient population. Further research is necessary to determine the proper scoring system for predicting ischaemic stroke in this subgroup.
- 1 July 2023
- Vol. 55 (3) , 327-331
Global Longitudinal Strain and Myocardial Work Index in Post-COVID-19 Syndrome with Mild Symptoms: A Case Series
The involvement of the cardiovascular system in COVID-19 is prevalent. The effect of SARS-COV-2 infection in both acute and recovery phases is called a post-COVID-19 syndrome. Considering the high prevalence of cardiac abnormalities after COVID-19, clinicians should continue to monitor cardiac function in COVID-19 patients after hospital discharge. Echocardiography is an accurate and accessible tool to assess cardiac function after COVID-19. Left-ventricle (LV) and right ventricle (RV) longitudinal strains are more sensitive to detecting subtle abnormalities than standard parameters, such as left-ventricle ejection fraction and tricuspid annular plane systolic excursion (TAPSE). Myocardial work index is a novel parameter including afterload to evaluate cardiac function. These parameters can give further information on cardiac function in COVID-19 patients. We presented two cases of COVID-19 with serial cardiac assessment using echocardiography.
- 1 July 2023
- Vol. 55 (3) , 327-331
Global Longitudinal Strain and Myocardial Work Index in Post-COVID-19 Syndrome with Mild Symptoms: A Case Series
The involvement of the cardiovascular system in COVID-19 is prevalent. The effect of SARS-COV-2 infection in both acute and recovery phases is called a post-COVID-19 syndrome. Considering the high prevalence of cardiac abnormalities after COVID-19, clinicians should continue to monitor cardiac function in COVID-19 patients after hospital discharge. Echocardiography is an accurate and accessible tool to assess cardiac function after COVID-19. Left-ventricle (LV) and right ventricle (RV) longitudinal strains are more sensitive to detecting subtle abnormalities than standard parameters, such as left-ventricle ejection fraction and tricuspid annular plane systolic excursion (TAPSE). Myocardial work index is a novel parameter including afterload to evaluate cardiac function. These parameters can give further information on cardiac function in COVID-19 patients. We presented two cases of COVID-19 with serial cardiac assessment using echocardiography.
- Open Access
- 1 January 2023
- Published by Hong Kong College of Cardiology in Journal of the Hong Kong College of Cardiology
- Vol. 30 (5) , 3
The Telltale of Left Atrial Thrombus Formation in Mitral Stenosis: Revisiting the Virchow’s Triad
Aims: This study was conducted to assess the relationship of simple hematological parameters with the incidence of left atrial thrombus in rheumatic mitral stenosis in addition to conventional contributing factors. Methods: A cross-sectional analytical study was conducted in patients with significant rheumatic stenosis from 1 January 2018 to 31 July 2021. Thrombus evaluation was confirmed by transthoracic or transesophageal echocardiography. Lab tests were performed within 10 days prior to the echocardiographic evaluation. Subjects with significant mitral regurgitation will be excluded. Logistic regression analysis was done to evaluate the relationship between each variable to the presence of a thrombus. Results: Of the 318 subjects with significant rheumatic mitral stenosis included in the study, 102 patients (32%) had a thrombus in the left atrium. Of all the patients, it was known that subjects with atrial fibrillation rhythm as much as 63.8% and sinus rhythm 36.2%. Atrial fibrillation rhythm (OR 2.39; 95% CI 1.10-5.20, p = 0.028), left ventricular ejection fraction ≥56.68 % (OR 0.42; 95% CI 0.23 - 0.77, p = 0.005), TAPSE ≥18.10 mm (OR 0.44; 95% CI 0.230 - 0.83, p = 0.011), and hematocrit ≥45.15% (OR 2.98; 95% CI 1.27 - 6.98, p = 0.012) are associated with left atrial thrombus. Conclusion: Increased hematocrit was significantly associated with the incidence of left atrial thrombus, which may have contributed to the statis and hypercoagulable state component of the Virchow’s triad.
- 1 January 2023
- Published by Hong Kong College of Cardiology in Journal of the Hong Kong College of Cardiology
- Vol. 30 (5) , 3
Open AccessThe Telltale of Left Atrial Thrombus Formation in Mitral Stenosis: Revisiting the Virchow’s Triad
Aims: This study was conducted to assess the relationship of simple hematological parameters with the incidence of left atrial thrombus in rheumatic mitral stenosis in addition to conventional contributing factors. Methods: A cross-sectional analytical study was conducted in patients with significant rheumatic stenosis from 1 January 2018 to 31 July 2021. Thrombus evaluation was confirmed by transthoracic or transesophageal echocardiography. Lab tests were performed within 10 days prior to the echocardiographic evaluation. Subjects with significant mitral regurgitation will be excluded. Logistic regression analysis was done to evaluate the relationship between each variable to the presence of a thrombus. Results: Of the 318 subjects with significant rheumatic mitral stenosis included in the study, 102 patients (32%) had a thrombus in the left atrium. Of all the patients, it was known that subjects with atrial fibrillation rhythm as much as 63.8% and sinus rhythm 36.2%. Atrial fibrillation rhythm (OR 2.39; 95% CI 1.10-5.20, p = 0.028), left ventricular ejection fraction ≥56.68 % (OR 0.42; 95% CI 0.23 - 0.77, p = 0.005), TAPSE ≥18.10 mm (OR 0.44; 95% CI 0.230 - 0.83, p = 0.011), and hematocrit ≥45.15% (OR 2.98; 95% CI 1.27 - 6.98, p = 0.012) are associated with left atrial thrombus. Conclusion: Increased hematocrit was significantly associated with the incidence of left atrial thrombus, which may have contributed to the statis and hypercoagulable state component of the Virchow’s triad.
- Open Access
- 31 December 2019
- Published by Herald Scholarly Open Access in Journal of Emergency Medicine, Trauma and Surgical Care
- Vol. 6 (2) , 1-5
Role Of Echocardiography In Diagnosis Arrhytmogenic Right Ventricle Dysplasia: A Rare Case
Arrhythmogenic right ventricular dysplasia/ cardiomyopathy (ARVD/C) is an inherited cardiomyopathy, clinically characterized by fibrous and fatty replacement of right ventricle and life-threatening ventricular arrhythmias.
- 31 December 2019
- Published by Herald Scholarly Open Access in Journal of Emergency Medicine, Trauma and Surgical Care
- Vol. 6 (2) , 1-5
Open AccessRole Of Echocardiography In Diagnosis Arrhytmogenic Right Ventricle Dysplasia: A Rare Case
Arrhythmogenic right ventricular dysplasia/ cardiomyopathy (ARVD/C) is an inherited cardiomyopathy, clinically characterized by fibrous and fatty replacement of right ventricle and life-threatening ventricular arrhythmias.
- Open Access
- 24 January 2019
- Published by PAGEPress Publications in Emergency Care Journal
- Vol. 15 (1) , 24-29
A health economic evaluation of using N-terminal pro brain natriuretic peptide for the management of acute heart failure: A pilot study in an Indonesian tertiary referral hospital
Heart failure represents a major health problem and economic burden also in development countries such as Indonesia. Based on current guidelines, the use of natriuretic peptides can improve diagnosis, risk stratification, and decrease in hospital length of stay. However, mostly due to the related high costs, many Indonesian physicians currently do not routinely use these biomarkers in their daily clinical practice. By comparing the results of guidance with N-terminal pro brain natriuretic peptide (NT-proBNP) and without NT-proBNP, this pilot study was aimed to determine the clinical effectiveness and costs of using natriuretic peptides in the management of acute heart failure (AHF) patients admitted at National Cardiovascular Center Harapan Kita Hospital, a tertiary referral hospital in Jakarta, Indonesia. This was a health economic evaluation using a single-blind, randomized controlled trial. AHF patients adjudicated following European Society of Cardiology guidelines were randomly assigned to the 2 groups: NT-proBNP group (group A) and control group (group B). In the group A, NT-proBNP level was obtained at admission and pre-discharge, with the target of achieving a decrease of ≥30%. Randomised patients were followed up to 90 days post-discharge to assess short-term outcomes and costs. In total, one hundred and twelve patients were enrolled, of whom 56 were randomized in group A and 56 patients in group B. Compared to Group B, in Group A the total costs of patients management resulted to be significantly higher (P<0.05), while no significant difference between the 2 groups was observed for inhospital length of stay, total mortality rate, rehospitalization, and emergency department visits within 90 days post-discharge. In this pilot study for the management of AHF at an Indonesian National Cardiovascular Center, the routine use of NT-proBNP compared to the non use, at hospital admission and discharge resulted into a significant increase of medical cost without any evident favourable impact on patients outcomes. Larger study in greater Asia Pacific populations should be performed to confirm these preliminary results.
- 24 January 2019
- Published by PAGEPress Publications in Emergency Care Journal
- Vol. 15 (1) , 24-29
Open AccessA health economic evaluation of using N-terminal pro brain natriuretic peptide for the management of acute heart failure: A pilot study in an Indonesian tertiary referral hospital
Heart failure represents a major health problem and economic burden also in development countries such as Indonesia. Based on current guidelines, the use of natriuretic peptides can improve diagnosis, risk stratification, and decrease in hospital length of stay. However, mostly due to the related high costs, many Indonesian physicians currently do not routinely use these biomarkers in their daily clinical practice. By comparing the results of guidance with N-terminal pro brain natriuretic peptide (NT-proBNP) and without NT-proBNP, this pilot study was aimed to determine the clinical effectiveness and costs of using natriuretic peptides in the management of acute heart failure (AHF) patients admitted at National Cardiovascular Center Harapan Kita Hospital, a tertiary referral hospital in Jakarta, Indonesia. This was a health economic evaluation using a single-blind, randomized controlled trial. AHF patients adjudicated following European Society of Cardiology guidelines were randomly assigned to the 2 groups: NT-proBNP group (group A) and control group (group B). In the group A, NT-proBNP level was obtained at admission and pre-discharge, with the target of achieving a decrease of ≥30%. Randomised patients were followed up to 90 days post-discharge to assess short-term outcomes and costs. In total, one hundred and twelve patients were enrolled, of whom 56 were randomized in group A and 56 patients in group B. Compared to Group B, in Group A the total costs of patients management resulted to be significantly higher (P<0.05), while no significant difference between the 2 groups was observed for inhospital length of stay, total mortality rate, rehospitalization, and emergency department visits within 90 days post-discharge. In this pilot study for the management of AHF at an Indonesian National Cardiovascular Center, the routine use of NT-proBNP compared to the non use, at hospital admission and discharge resulted into a significant increase of medical cost without any evident favourable impact on patients outcomes. Larger study in greater Asia Pacific populations should be performed to confirm these preliminary results.